source
- Acadia’s Alzheimer’s psychosis drug misses Phase 2 goals, but moves to revised Phase 3Acadia Pharmaceuticals announced that its experimental treatment for psychosis linked to Alzheimer’s disease failed to meet the primary endpoints in a Phase 2 trial. The company said the data stil…
- Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trialEli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…